US-based biotechnology companies Exelixis and MSD have partnered to assess the potential of combining their respective cancer ...

Last week, the biotech sector was in focus, with regular pipeline and regulatory updates. Vanda Pharmaceuticals Inc. VNDA was ...

Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Stephen Willey ...

The company is running phase 3 studies for a new product, zanzalintinib, including in treating colorectal cancer -- the second-leading cause of cancer death in the world. That's even though ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

Stocks with solid growth prospects aren't always trading for exorbitant sticker prices. Whether they recently conducted a stock split, their shares dropped unjustifiably, or the market isn't ...